Clinical Research Directory
Browse clinical research sites, groups, and studies.
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
Sponsor: Second Xiangya Hospital of Central South University
Summary
The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage IIIB-C driver-negative NSCLC in the MDT model, so as to accurately guide clinical diagnosis and treatment.
Official title: The Role of Dynamic Circulating Tumor DNA-Molecular Residual Disease (ctDNA-MRD) Testing in Stage IIIB-C Oncogene-negative NSCLC Patients Treated With Induction Chemoimmunotherapy in the Multidisciplinary Team (MDT) Model of Diagnosis and Treatment
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2023-04
Completion Date
2029-03
Last Updated
2023-04-20
Healthy Volunteers
No
Conditions
Interventions
NGS and ctDNA-MRD detection
NGS and ctDNA-MRD detection
Locations (1)
Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China
Changsha, Hunan, China